Cullinan Associates Inc. reduced its position in Johnson & Johnson (NYSE:JNJ) by 5.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 136,958 shares of the company’s stock after selling 7,282 shares during the quarter. Johnson & Johnson makes up about 1.4% of Cullinan Associates Inc.’s holdings, making the stock its 8th largest position. Cullinan Associates Inc.’s holdings in Johnson & Johnson were worth $18,118,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. NEXT Financial Group Inc increased its position in Johnson & Johnson by 3.1% in the second quarter. NEXT Financial Group Inc now owns 36,521 shares of the company’s stock worth $4,831,000 after buying an additional 1,098 shares during the last quarter. Private Capital Advisors Inc. grew its position in shares of Johnson & Johnson by 11.9% in the second quarter. Private Capital Advisors Inc. now owns 11,008 shares of the company’s stock valued at $1,456,000 after purchasing an additional 1,168 shares in the last quarter. CHICAGO TRUST Co NA grew its position in shares of Johnson & Johnson by 8.0% in the second quarter. CHICAGO TRUST Co NA now owns 24,437 shares of the company’s stock valued at $3,233,000 after purchasing an additional 1,800 shares in the last quarter. Hills Bank & Trust Co. grew its position in shares of Johnson & Johnson by 3.8% in the second quarter. Hills Bank & Trust Co. now owns 43,568 shares of the company’s stock valued at $5,764,000 after purchasing an additional 1,587 shares in the last quarter. Finally, Swedbank grew its position in shares of Johnson & Johnson by 0.4% in the second quarter. Swedbank now owns 3,448,215 shares of the company’s stock valued at $456,164,000 after purchasing an additional 14,681 shares in the last quarter. 65.90% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Shares Sold by Cullinan Associates Inc.” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-shares-sold-by-cullinan-associates-inc/1615879.html.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.02% during midday trading on Friday, reaching $133.22. The company’s stock had a trading volume of 2,469,506 shares. The company’s 50-day moving average price is $132.23 and its 200-day moving average price is $129.87. The company has a market cap of $357.56 billion, a PE ratio of 22.54 and a beta of 0.78. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. During the same quarter in the prior year, the business posted $1.74 EPS. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. Johnson & Johnson’s payout ratio is 56.76%.

In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

JNJ has been the subject of several recent research reports. Cowen and Company reiterated an “outperform” rating and issued a $143.00 price target on shares of Johnson & Johnson in a research report on Tuesday, June 13th. Royal Bank Of Canada reiterated a “buy” rating and issued a $128.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 15th. Jefferies Group LLC reiterated a “hold” rating and issued a $140.00 price target on shares of Johnson & Johnson in a research report on Friday, June 16th. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Finally, Morgan Stanley lifted their price target on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. Five analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $134.79.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.